scholarly journals Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria

Theranostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 3254-3262
Author(s):  
Erik M. Velez ◽  
Bhushan Desai ◽  
Lingyun Ji ◽  
David I. Quinn ◽  
Patrick M. Colletti ◽  
...  
Keyword(s):  
Treatment Response ◽  
Response Criteria ◽  
Prognostic Implication ◽  
Recist 1.1 ◽  
Psa Response ◽  
Percist 1.0

scholarly journals 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results

2020 ◽  
Author(s):  
L. M. Mittlmeier ◽  
M. Unterrainer ◽  
S. Rodler ◽  
A. Todica ◽  
N. L. Albert ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Treatment Response ◽  
Renal Cell ◽  
Systemic Treatment ◽  
Response Assessment ◽  
Recist 1.1 ◽  
Psma Pet ◽  
Pet Ct

Abstract Introduction Tyrosine kinase (TKI) and checkpoint inhibitors (CI) prolonged overall survival in metastatic renal cell carcinoma (mRCC). Early prediction of treatment response is highly desirable for the individualization of patient management and improvement of therapeutic outcome; however, serum biochemistry is unable to predict therapeutic efficacy. Therefore, we compared 18F-PSMA-1007 PET imaging for response assessment in mRCC patients undergoing TKI or CI therapy compared to CT-based response assessment as the current imaging reference standard. Methods 18F-PSMA-1007 PET/CT was performed in mRCC patients prior to initiation of systemic treatment and 8 weeks after therapy initiation. Treatment response was evaluated separately on 18F-PSMA-PET and CT. Changes on PSMA-PET (SUVmean) were assessed on a per patient basis using a modified PERCIST scoring system. Complete response (CRPET) was defined as absence of any uptake in all target lesions on posttreatment PET. Partial response (PRPET) was defined as decrease in summed SUVmean of > 30%. The appearance of new, PET-positive lesions or an increase in summed SUVmean of > 30% was defined as progressive disease (PDPET). A change in summed SUVmean of ± 30% defined stable disease (SDPET). RECIST 1.1 criteria were used for response assessment on CT. Results of radiographic response assessment on PSMA-PET and CT were compared. Results Overall, 11 mRCC patients undergoing systemic treatment were included. At baseline PSMA-PET1, all mRCC patients showed at least one PSMA-avid lesion. On follow-up PET2, 3 patients showed CRPET, 3 PRPET, 4 SDPET, and 1 PDPET. According to RECIST 1.1, 1 patient showed PRCT, 9 SDCT, and 1 PDCT. Overall, concordant classifications were found in only 2 cases (2 SDCT + PET). Patients with CRPET on PET were classified as 3 SDCT on CT using RECIST 1.1. By contrast, the patient classified as PRCT on CT showed PSMA uptake without major changes during therapy (SDPET). However, among 9 patients with SDCT on CT, 3 were classified as CRPET, 3 as PRPET, 1 as PDPET, and only 2 as SDPET on PSMA-PET. Conclusion On PSMA-PET, heterogeneous courses were observed during systemic treatment in mRCC patients with highly diverging results compared to RECIST 1.1. In the light of missing biomarkers for early response assessment, PSMA-PET might allow more precise response assessment to systemic treatment, especially in patients classified as SD on CT.

A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Anatomic Imaging Biomarkers

2013 ◽  
Vol 201 (2) ◽  
pp. 237-245 ◽  
Author(s):  
Pedram Rezai ◽  
Mark J. Pisaneschi ◽  
Chun Feng ◽  
Vahid Yaghmai
Keyword(s):  
Treatment Response ◽  
Response Criteria ◽  
Imaging Biomarkers ◽  
Oncologic Imaging

Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT – RECIST 1.1 vs. PERCIST 1.0

2018 ◽  
Vol 101 ◽  
pp. 65-71 ◽  
Author(s):  
Soichi Odawara ◽  
Kazuhiro Kitajima ◽  
Takayuki Katsuura ◽  
Yasunori Kurahashi ◽  
Hisashi Shinohara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Tumor Response ◽  
Recist 1.1 ◽  
Pet Ct ◽  
Percist 1.0 ◽  
Fdg Pet Ct ◽  
Response To Neoadjuvant Chemotherapy

Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e574-e574 ◽  
Author(s):  
Allison H. Feibus ◽  
Jeffrey R. Guccione ◽  
Ashwin Vasudevamurthy ◽  
Elisa M. Ledet ◽  
Patrick Cotogno ◽  
...  
Keyword(s):  
Treatment Response ◽  
Median Time ◽  
Specific Antigen ◽  
Early Assessment ◽  
Median Length ◽  
Duration Of Treatment ◽  
Primary Resistance ◽  
Response Predictors ◽  
Psa Response ◽  
Psa Nadir

e574 Background: Abiraterone (Abi) and enzaleutamide (Enza) are first-line agents for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Primary resistance is well-documented, but little data exists for rapid treatment responders. This study intended to further characterize patients with early prostate-specific antigen (PSA) decline. Methods: A single-institution retrospective review was performed on 123 mCRPC patients treated with Abi and/or Enza. PSA was recorded every 4 weeks for the duration of treatment. The primary endpoint was to describe PSA response, including sensitivities and specificities, as a predictor of later treatment response (defined as ≥50% decrease in PSA from baseline). Additional clinical covariates were also evaluated as treatment-response predictors. Results: A PSA response to Abi was achieved in 52/123 (42%) of patients. Median time to PSA nadir was 37 days. 30/52 (58%) patients responded to the drug within 4 weeks. Median length of time on drug was 110 days. A PSA response to Enza was achieved in 21/123 (17%) of patients. Median time to PSA nadir was 140 days. 18/21 (86%) of patients responded to the drug within 4 weeks. Median length of time on drug was 161 days. Conclusions: Percentage of PSA decline and time to drug response for Enza and Abi are important variables that can serve as reliable way for clinicians to predict long-term PSA response. It is vital to make appropriate treatment modifications for patients that do not display early PSA response. [Table: see text]

Đáp ứng sớm của điều trị xạ trị lập thể định vị thân ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn I

2021 ◽  
Vol 16 (DB4) ◽  
Author(s):  
Phạm Văn Luận ◽  
Nguyễn Đình Tiến ◽  
Lê Ngọc Hà ◽  
Bùi Quang Biểu
Keyword(s):  
Recist 1.1 ◽  
Pet Ct ◽  
Percist 1.0

Mục tiêu: Đánh giá đáp ứng sớm điều trị xạ trị lập thể định vị thân ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn I (T1-T2aN0M0). Đối tượng và phương pháp: Nghiên cứu tiến cứu, theo dõi dọc 25 bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn T1-T2aN0M0 được điều trị xạ trị lập thể định vị thân và đánh giá mỗi 3 tháng từ tháng 01/2015 đến tháng 12/2020. Đáp ứng điều trị sớm sau 3 tháng được đánh giá theo tiêu chuẩn RECIST 1.1 và PERCIST 1.0, đánh giá tác dụng không mong muốn theo tiêu chuẩn của Viện Ung thư quốc gia Mỹ. Kết quả: Tuổi trung bình là 65,32 tuổi, kích thước trung bình của khối u trên CT ngực là 3,33cm, trên PET/CT 3,21cm, giá trị FDG trung bình 8,01. Giai đoạn của khối u đa số là T2a (56%). Bệnh nhân được chỉ định SBRT do COPD chiếm 60%. Liều điều trị trung bình 4208cGy, 40% điều trị 1 phân liều, còn lại là 3 - 5 phân liều. Theo RECIST, không có đáp ứng hoàn toàn, 44% đáp ứng 1 phần, 36% bệnh ổn định, 5 bệnh nhân có bệnh tiến triển, tỉ lệ đáp ứng khách quan là 44%, tỷ lệ kiểm soát bệnh là 80%. Theo PERCIST, có 1 bệnh nhân đạt đáp ứng hoàn toàn, các tỷ lệ khác lần lượt là 68%, 24%, 8%, 68% và 92%, sự khác biệt giữa 2 tiêu chuẩn có ý nghĩa thống kê với p<0,05. CEA và giá trị SUVmax có mối liên quan đến đáp ứng sau điều trị (p<0,05). Tác dụng không mong muốn hay gặp là viêm phổi do xạ: 11 bệnh nhân, chủ yếu là độ 1, không có viêm phổi do xạ độ 4, 5. Không có sự thay đổi về chức năng hô hấp của bệnh nhân sau điều trị SBRT. Kết luận: SBRT là phương pháp điều trị cho đáp ứng tốt ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn I với tỷ lệ kiểm soát bệnh 92%, đồng thời đây là một biện pháp điều trị an toàn cho người bệnh.

scholarly journals 330. TREATMENT RESPONSE CRITERIA FOR ANCA-ASSOCIATED VASCULITIS: RESULTS OF A SCOPING REVIEW

Rheumatology ◽  
2019 ◽  
Vol 58 (Supplement_2) ◽  
Author(s):  
Sara Monti ◽  
Kaitlin Quinn ◽  
Robin Christensen ◽  
Alfred Mahr ◽  
Christian Pagnoux ◽  
...  
Keyword(s):  
Treatment Response ◽  
Scoping Review ◽  
Response Criteria ◽  
Anca Associated Vasculitis
Sign in / Sign up

Export Citation Format

Share Document